Evidence map›Paper›PMID 36561346›Full record

ReviewFrontiers in pharmacology2022

Research progress on effects of traditional Chinese medicine on myocardial ischemia-reperfusion injury: A review.

Na Xing, Xiao-Tong Long, Hui-Juan Zhang, Li-Dan Fu, Jian-Yuan Huang, Abdallah Iddy Chaurembo, Francis Chanda, Yun-Jing Xu, Chi Shu, Kai-Xuan Lin and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Na XingZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Xiao-Tong LongZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Hui-Juan ZhangZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Li-Dan FuZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Jian-Yuan HuangZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Abdallah Iddy ChauremboZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Francis ChandaZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Yun-Jing XuZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Chi ShuZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Kai-Xuan LinDepartment of Cardiology, Zhongshan Hospital Affiliated with Guangzhou University of Chinese Medicine (Zhongshan Hospital of Traditional Chinese Medicine), Zhongshan, Guangdong, China.
Ke YangZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.
Han-Bin LinZhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic heart disease (IHD) is a high-risk disease in the middle-aged and elderly population. The ischemic heart may be further damaged after reperfusion therapy with percutaneous coronary intervention (PCI) and other methods, namely, myocardial ischemia-reperfusion injury (MIRI), which further affects revascularization and hinders patient rehabilitation. Therefore, the investigation of new therapies against MIRI has drawn great global attention. Within the long history of the prevention and treatment of MIRI, traditional Chinese medicine (TCM) has increasingly been recognized by the scientific community for its multi-component and multi-target effects. These multi-target effects provide a conspicuous advantage to the anti-MIRI of TCM to overcome the shortcomings of single-component drugs, thereby pointing toward a novel avenue for the treatment of MIRI. However, very few reviews have summarized the currently available anti-MIRI of TCM. Therefore, a systematic data mining of TCM for protecting against MIRI will certainly accelerate the processes of drug discovery and help to identify safe candidates with synergistic formulations. The present review aims to describe TCM-based research in MIRI treatment through electronic retrieval of articles, patents, and ethnopharmacology documents. This review reported the progress of research on the active ingredients, efficacy, and underlying mechanism of anti-MIRI in TCM and TCM formulas, provided scientific support to the clinical use of TCM in the treatment of MIRI, and revealed the corresponding clinical significance and development prospects of TCM in treating MIRI.

Indexed as

cardioprotective effectsmolecular mechanismsmyocardial ischemia–reperfusion injurypathogenesistraditional Chinese medicine

Identifiers

PMID36561346
PMCPMC9763941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.